1. Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 2019; 78: 365-71. doi: 10.1136/annrheumdis-2018-214502
|
2. Jesus D, Matos A, Henriques C, et al. Response to: 'SLE-DAS: ready for routine use' by Mathew et al. Ann Rheum Dis 2019. doi: 10.1136/annrheumdis-2019-215794. |
3. Jesus D, Matos A, Henriques C, et al. Response to: 'Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population', by Rodriguez-Gonzalez et al. Ann Rheum Dis 2019. doi: 10.1136/annrheumdis-2019-216110. |
4. Jesus D, Zen M, Doria A, et al. Response to: 'Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort', by Hassan et al. Ann Rheum Dis 2019. doi: 10.1136/annrheumdis-2019-215430 |
5. Jesus D, Matos A, Henriques C, et al. FRI0641 Detection of changes in SLE disease activity is highly improved with SLE-DAS as compared to SLEDAI: derivation and preliminary validation of the sle disease activity score (SLE-DAS). Ann Rheum Dis 2018; 77: 842-3. doi: 10.1136/annrheumdis-2018-eular.3161 |
6. Larosa M, Costedoat-Chalumeau N, Guettrot-Imbert G, et al. SLE-DAS in the first trimester of gestation predicts maternal lupus flares later in pregnancy. Front Pharmacol 2021;12:660123. doi:10.3389/fphar.2021.660123 |
7. Jesus D, Larosa M, Henriques C, et al. Systemic lupus erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis2021;80(12):1568–74. doi:10.1136/annrheumdis-2021-220363 |
8. Assunção H, Jesus D, Larosa M, et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford) 2022;61(8):3309–16. doi:10.1093/rheumatology/keab895 |
9. Saraiva L, Cunha RN, Jesus D, et al. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study. Rheumatology (Oxford) 2024;63(4):1123–29. doi:10.1093/rheumatology/kead353 |
10. Jesus D, Matos A, Henriques C, et al. Performance of the SLE-DAS in randomized controlled trials: post-hoc analysis of the MUSE, TULIP-1 and TULIP-2 anifrolumab studies. Arthritis Care Res (Hoboken) 2024; doi:10.1002/acr.25305 |
11. Jesus D, Matos A, Henriques C, et al. SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post-hoc study of anifrolumab phase II and III studies. Lupus Sci Med2025;12:e001499. doi:10.1136/lupus-2025-001499 |